4.6. Alterations in Myocardial Performance
cardiotoxic cancer, cancer, decline in cardiac function, Cardiotoxic cancer, cardiotoxicity, LV dysfunction
CANCER, COMPLICATIONS
Although, GLS is a more sensitive method of assessing LV systolic function than LVEF, it has the disadvantage of being dependent on LV loading conditions. Non-invasive assessment of myocardial work indices improves assessment of myocardial performance by incorporating load and strain in the analysis. Cardiotoxic cancer treatments adversely affect myocardial work indices, indicating a decline in cardiac function. The extent and timing of these changes may vary depending on the type and dose of cancer treatment and individual patient factors [Our data support previous evidence that early assessment of subclinical cardiotoxicity (using measurement of Tn I, NT-proBNP, GLS, and MW indices) in patients undergoing cardiotoxic cancer therapy may lead to early detection of LV dysfunction and timely initiation of appropriate management to prevent serious complications and improve survival in cancer patients.We believe that the cardioprotective properties of ivabradine could be demonstrated in a larger population of cancer patients, including those at higher risk of cardiotoxicity.